Vascular Disrupting Agent ASA404 Fails in First Line Phase III Trial for Advanced NSCLC
Article
Unfortunately, yesterday brought bad news in the form of another negative phase III trial for advanced NSCLC, this one the ATTRACT-1 trial of carboplatin/taxol (paclitaxel) with or without ASA404, which is in a class of drugs called "vascular disrupting agents" that I described in a post back in 2007.